<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807365</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00005793</org_study_id>
    <secondary_id>2002P-001781</secondary_id>
    <secondary_id>P01-AG0059-21</secondary_id>
    <nct_id>NCT00807365</nct_id>
  </id_info>
  <brief_title>Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly</brief_title>
  <acronym>PP2</acronym>
  <official_title>Six Month Treatment of GHRH in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of a naturally occurring hormone, called
      Growth Hormone Releasing Hormone (GHRH), on the muscle, bone and fat tissues of the body.
      GHRH stimulates the production of growth hormone (GH), which regulates the build up of many
      tissues in the body, including muscles and bones. Many elderly people have low levels of GH.
      The overall goal of this research is to determine the effectiveness of GHRH to raise levels
      of GH and improve these body tissues. The purpose of the tests is to measure how the body
      handles sugar, fat, and proteins. GH can affect your body's use of sugar, fat and proteins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growth hormone (GH) is a major anabolic hormone that exerts important stimulatory effects on
      protein synthesis. Many of the peripheral tissue effects of GH are mediated by insulin-like
      growth factor I (IGF-I), produced systemically by the liver or locally in tissues in response
      to GH stimulation. IGF-I in turn regulates GH secretion by negative feedback mechanisms at
      the pituitary gland. Several investigators have shown that aging is associated with a
      decrease in spontaneous GH secretion and IGF-I levels. GH levels decline by 14% for each
      decade after puberty, and, in healthy 59-98 year old men, IGF-I levels below the 2.5
      percentile of younger men are present in 85%. Reduction of GH release in aging is thought to
      be associated with an increase in somatostatin tone, decrease in hypothalamic GHRH output,
      and diminished response to GHRH. The fact that aging is accompanied by a decrease in protein
      synthesis leading to a loss of lean body mass (LBM) and a gain in body fat suggests that a
      decrease in GH secretion may contribute to these changes. It has been hypothesized that
      restoration of GH level in the elderly to the levels observed in younger individuals may lead
      to improvements in body composition.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left JHU
  </why_stopped>
  <start_date type="Actual">December 17, 2007</start_date>
  <completion_date type="Actual">April 29, 2010</completion_date>
  <primary_completion_date type="Actual">April 29, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lean Body Mas</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>GHRH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Hormone-Releasing Hormone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GHRH</intervention_name>
    <description>GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, &amp; 5:00 AM for 6 months.</description>
    <arm_group_label>GHRH</arm_group_label>
    <other_name>Growth Hormone-Releasing Hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of low GH levels as assessed by a fasting IGF-1 level &lt;135ng/ml.

          -  Volunteers whose BMI is above normal range and below extreme obesity (BMI 25-40
             kg/m2).

        Exclusion Criteria:

          -  Diabetes.

          -  Known coronary artery disease.

          -  Liver, peptic or inflammatory bowel disease. Renal or hematologic disease.

          -  Hematocrit &lt;30% or &gt;50%.

          -  Clinically significant prostate hypertrophy.

          -  Elevated Prostate specific antigen (PSA) (4ng/ml).

          -  Prostate &amp; breast cancer.

          -  History of malignancy &lt;5 years other than basal cell of the skin.

          -  Chronic pulmonary disease or other systemic disorders.

          -  Use of certain drugs (such as thiazide diuretics, beta-blockers, steroids (except for
             replacement doses), coumadin, and or androgen supplements).

          -  Peanut allergy.

          -  Gross physical impairment.

          -  Sleep apnea.

          -  Uncontrolled hypertension(blood pressure &gt;160/95 and or requiring more than two
             antihypertensive medications).

          -  A clinically worrisome mammogram in women.

          -  Exercise training (&gt;2x/wk for 20 min at a level that produces sweating) in the last 6
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariush Elahi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth L. Minaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <results_first_submitted>March 16, 2017</results_first_submitted>
  <results_first_submitted_qc>March 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2017</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth Hormone-Releasing Hormone</keyword>
  <keyword>Growth Hormone Insufficiency</keyword>
  <keyword>Aging</keyword>
  <keyword>Growth Hormone</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Hormones, Hormone Substitutes, and Hormone Antagonists</keyword>
  <keyword>Hormones</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
    <mesh_term>Hormones, Hormone Substitutes, and Hormone Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GHRH</title>
          <description>Growth Hormone-Releasing Hormone
GHRH: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, &amp; 5:00 AM for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GHRH</title>
          <description>Growth Hormone-Releasing Hormone
GHRH: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, &amp; 5:00 AM for 6 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lean Body Mas</title>
        <time_frame>2 years</time_frame>
        <population>Study terminated prior to collection of data</population>
        <group_list>
          <group group_id="O1">
            <title>GHRH</title>
            <description>Growth Hormone-Releasing Hormone
GHRH: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, &amp; 5:00 AM for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mas</title>
          <population>Study terminated prior to collection of data</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GHRH</title>
          <description>Growth Hormone-Releasing Hormone
GHRH: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, &amp; 5:00 AM for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johns Hopkins ClinicalTrials.gov Program</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4105506484</phone>
      <email>registerclinicaltrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

